Cargando…

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis

A fundamental process in the development and progression of heart failure is fibrotic remodeling, characterized by excessive deposition of extracellular matrix proteins in response to injury. Currently, therapies that effectively target and reverse cardiac fibrosis are lacking, warranting novel ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bracco Gartner, Thomas C. L., Crnko, Sandra, Leiteris, Laurynas, van Adrichem, Iris, van Laake, Linda W., Bouten, Carlijn V. C., Goumans, Marie José, Suyker, Willem J. L., Sluijter, Joost P. G., Hjortnaes, Jesper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963358/ https://www.ncbi.nlm.nih.gov/pubmed/35360018 http://dx.doi.org/10.3389/fcvm.2022.854314

Ejemplares similares

Anti-fibrotic Effects of Cardiac Progenitor Cells in a 3D-Model of Human Cardiac Fibrosis
por: Bracco Gartner, Tom C. L., et al.
Publicado: (2019)

Myocardial Disease and Long-Distance Space Travel: Solving the Radiation Problem
por: Meerman, Manon, et al.
Publicado: (2021)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients
por: Crnko, Sandra, et al.
Publicado: (2020)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

Radiation Induces Valvular Interstitial Cell Calcific Response in an in vitro Model of Calcific Aortic Valve Disease
por: Meerman, Manon, et al.
Publicado: (2021)

Morning pulmonary artery pressure measurements by CardioMEMS are most stable and recommended for pressure trends monitoring
por: Crnko, S., et al.
Publicado: (2021)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

The circadian clock remains intact, but with dampened hormonal output in heart failure
por: Crnko, Sandra, et al.
Publicado: (2023)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Single-cell analysis of human fetal epicardium reveals its cellular composition and identifies CRIP1 as a modulator of EMT
por: Streef, Thomas J., et al.
Publicado: (2023)

Editorial: Heart Valve Tissue Engineering: Are We Ready for Clinical Translation?
por: Hjortnaes, Jesper, et al.
Publicado: (2021)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Sequential use of human-derived medium supplements favours cardiovascular tissue engineering
por: Vis, Paul W Riem, et al.
Publicado: (2012)

Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel
por: van der Ven, Casper F. T., et al.
Publicado: (2021)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Engineering a 3D-Bioprinted Model of Human Heart Valve Disease Using Nanoindentation-Based Biomechanics
por: van der Valk, Dewy C., et al.
Publicado: (2018)

Integrative Multi-Omics Analysis in Calcific Aortic Valve Disease Reveals a Link to the Formation of Amyloid-Like Deposits
por: Heuschkel, Marina A., et al.
Publicado: (2020)

SCA1(+) Cells from the Heart Possess a Molecular Circadian Clock and Display Circadian Oscillations in Cellular Functions
por: Du Pré, Bastiaan C., et al.
Publicado: (2017)

Variation within Variation: Comparison of 24-h Rhythm in Rodent Infarct Size between Ischemia Reperfusion and Permanent Ligation
por: du Pré, Bastiaan, et al.
Publicado: (2017)

Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes
por: Maas, Renee G.C., et al.
Publicado: (2021)

Human cardiomyocyte progenitor cells: a short history of nearly everything
por: Vliet, Patrick, et al.
Publicado: (2012)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Human pluripotent stem cell-derived cardiomyocytes align under cyclic strain when guided by cardiac fibroblasts
por: Mostert, Dylan, et al.
Publicado: (2022)

Mimicking Cardiac Fibrosis in a Dish: Fibroblast Density Rather than Collagen Density Weakens Cardiomyocyte Function
por: van Spreeuwel, Ariane C.C., et al.
Publicado: (2017)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oneeaeirmlb25126k3edef0km1